WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced that Maria Teresa Hilado, chief financial officer of Allergan, has been named to PPD’s board of directors.
“Tessa Hilado’s 30 years of global financial experience and keen understanding of the pharmaceutical industry make her an ideal addition, and we are pleased to welcome her to our board of directors,” said David Simmons, chairman and chief executive officer of PPD. “Her demonstrated commitment to strong financial stewardship complements PPD’s dedication to disciplined, strategic investment in innovative client solutions to accelerate drug development and improve patient health.”
Hilado has served as CFO of Allergan since December 2014, and she plans to retire from the company in the first quarter of 2018. Prior to joining Allergan, Hilado served as senior vice president, finance and treasurer of PepsiCo Inc. from 2009 to 2014. She previously served as vice president and treasurer for Schering-Plough Corp. from 2008 to 2009 and had spent more than 17 years with General Motors Co. in leadership roles of increasing responsibility, including assistant treasurer from 2006 to 2008 and CFO, GMAC Commercial Finance LLC from 2001 to 2005. She began her career with Far East Bank and Trust Co. in Manila, Philippines.
“PPD continues to set new benchmarks for excellence in drug development, and I look forward to joining the seasoned, creative leaders on the board for the next chapter of the company’s growth,” Hilado said. “PPD and I share a firm belief that a continued emphasis on a strong financial foundation is fundamental to enabling innovative drug development strategies to speed life-changing medical therapies to patients.”
Hilado currently serves on the board of directors of H.B. Fuller Co. She earned a bachelor’s degree in management engineering from Ateneo de Manila University in the Philippines, and an MBA from the University of Virginia’s Darden School of Business Administration.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.